Back to top

Fujifilm (FUJIY) Invests ??170M on TOKIWA-Bio's Tech-License

Read MoreHide Full Article

FUJIFILM Holdings Corporation (FUJIY - Free Report) recently made a ¥170-million investment in Japan-based bioventure — TOKIWA-Bio, Inc. (TOKIWA-Bio) — in order to enhance its in-house renewing medicine products portfolio. The company intends to acquire TOKIWA-Bio’s transgenic technology with this investment.

Over the last three months, Fujifilm’s shares have yielded a return of 7.3%, as against 7.6% loss incurred by the industry.

The company is poised to grow on the back of strong innovation, strategic business acquisitions and efficient operations.
 

Inside the Headlines  

Fujifilm’s U.S. subsidiary — Cellular Dynamics International, Inc. (“CDI”) — currently manages its iPS -cell related business. CDI supplies different types of iPS cell-resultant cells as well as other materials to many renowned pharmaceutical companies across the globe. It also creates its own regenerative medicine products and manufactures iPS cells for Fujifilm’s research purposes.  

TOKIWA-Bio discovers hands-on applications of therapeutic drugs based on advanced transgenic technologies. The company is currently applying its Stealth RNA Vector technology to create gene-therapy medicines for curing rare diseases. Moreover, TOKIWA-Bio is developing iPS cells and genetically-engineered cells for biopharmaceuticals.

Through the ¥170-million deal, Fujifilm will win TOKIWA-Bio's transgenic technology’s license, for its iPS cell research and production actions. Going forward, the company intends to discover unique iPS cell-derived distinguished cells and simultaneously expand its existing product lineup.

Zacks Rank and Stocks to Consider

Fujifilm currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same space are listed below:

Axcelis Technologies, Inc. (ACLS - Free Report) currently sports a Zacks Rank #1 (Strong Buy) and has a positive average earnings surprise of 25.22% for the last four quarters. You can see the complete list of today’s Zacks #1 Rank stocks here.

Agilent Technologies, Inc. (A - Free Report) carries a Zacks Rank #2 (Buy) and has a positive average earnings surprise of 13.98% for the trailing four quarters.

Acxiom Corporation (ACXM - Free Report) also holds a Zacks Rank #2 and has a positive average earnings surprise of 28.45% during the same time frame.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>



More from Zacks Analyst Blog

You May Like